PAR.AX

Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited

A$0.25

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

153.48M

Avg Volume

1.95M

EPS

-A$0.15

52W High

A$0.47

52W Low

A$0.14

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

1.35

P/B Ratio

40.83

EV/EBITDA

-2.27

Margins

Gross Margin 0.0%

Operating Margin 156513.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(457.0%)

Return on Assets

(138.8%)

Liquidity & Leverage

Current Ratio

1.10

Quick Ratio

1.07

Debt / Equity

2.16

Total Cash

15.44M

Total Debt

7.51M

About

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.